MicroSalt reports unaudited H1 revenue of US$1.4m, net loss US$1.5m

For best results when printing this announcement, please click on link below: RNS Number: 7363W MicroSalt PLC 29 September 2026 29 September 2026 MicroSalt plc ("MicroSalt", “the Company" or the “Group") Unaudited Half-yearly Report for the period ending 30 June 2026 MicroSalt plc, (AIM: SALT) a company commercialising a patented technology to produce full-flavour low-sodium salt, is pleased to announce its unaudited results for the six-month period ended 30 June 2026 (“H1 2026” or the “Period”). 8m) up 67% reflecting our ongoing focus on bulk sales. * Gross margins improved from 1% (H1 2025) to 12% during the period.

The Company expects further margin improvement reflecting increased production efficiencies, manufacturing scale and a growing proportion of higher end margin commercial successes. 9m) reflecting improvement to bulk sales as well as developing economies of scale in both production and sales efforts. * Commenced commercialisation and consumer testing with a number of multinational FMCG companies and food manufacturers for bulk salt. 1m for the balance of 2026.

5m. Achievement of this full year revenue expectation is dependent upon the timing of the rollout with Customer 3, and their launch of at least 17 new formulations in Q4 2026. * The strong pipeline of significant customer projects, together with the rollout mentioned above, leaves the Board confident with the $15m sales forecast for FY27. * Important R&D projects focused on MicroSalt Premium and its sales rollout which will lead to additional markets and new potential applications both short- and long-term.

0m before expenses. 4m of convertible lean notes into equity, the shares of which were admitted to trading on AIM on 25 September 2026. This leaves the Company with significantly reduced debt levels and cash available until the Company becomes trading cash flow positive which is expected when the customer 3 rollout noted above reaches forecast volumes. Rick Guiney, CEO of MicroSalt commented: “The first half of 2026 demonstrates the continued strength of our commercial model.

4 billion healthier servings of MicroSalt globally. “Importantly, momentum continues to be driven by recurring customer demand, expanding product adoption and a growing commercial pipeline. While the qualification process for large food manufacturers can be extensive, requiring rigorous testing, validation and reformulation work, successful adoption typically reflects a significant investment by customers in our product and helps foster long-term commercial relationships.

MicroSalt is being rolled out into one of the marquee product lines of one of the largest snack food companies in the world, providing absolute validation of our products efficacy in reducing salt, whilst keeping the flavour profile unchanged. “We believe MicroSalt is increasingly establishing itself as a commercially proven solution for food manufacturers seeking meaningful sodium reduction without compromising taste, functionality or clean-label requirements.

" For more information, please visit ( ), follow on X @microSaltPLC or contact: MicroSalt plc Via Gracechurch PR Rick Guiney, CEO Gary Urmston, Interim CFO Zeus (Nominated adviser and broker) +44 (0)20 3829 5000 David Foreman / Ed Beddows (Investment Banking) Nick Searle (Head of Equity Capital Markets) Gracechurch Group (Financial PR) +44 (0)20 4582 3500 Heather Armstrong / Alexis Gore / Rebecca Scott About MicroSalt MicroSalt is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers.

Using proprietary micron-sized particles, MicroSalt delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges. Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030.

The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year. Operational since 2018, MicroSalt has established a defensible IP portfolio, holding a granted US patent and 14 pending applications worldwide. These protections create significant barriers to entry in a market expected to grow exponentially as regulation and consumer demand accelerate.

MicroSalt is ideally positioned for scale and market leadership, with clear pathways into food manufacturing, consumer channels, and ultimately the broader £10+ billion global salt market. MicroSalt is more than a healthier alternative-it is a disruptive, category-defining solution poised to deliver significant commercial and societal impact. Chief Executive Officer’s statement Introduction Our mission is to reduce excess sodium consumption which significantly contributes to hypertension and heart disease, by providing a full-flavour salt with approximately 50% less sodium than traditional salt for food manufacturers and consumers.

To achieve this, we have developed a patent protected and scalable manufacturing process that produces a salt crystal that is approximately 100 times smaller than traditional salt. Due to its micron sized particles, MicroSalt has improved adhesion to food (compared with traditional salt crystals) and dissolves much faster on the tongue, thereby delivering the same sense of saltiness but using approximately half the amount of sodium. H1 2026 was an exciting period for MicroSalt where we saw success in our continued R&D efforts, infrastructure and staffing improvements, and strategic growth.

As we promote our vision of a healthier future through reduced sodium in today’s diets, we are discovering more possibilities and commercial opportunities. We have established an active B2B pipeline for future growth and we have created a groundbreaking innovative product that is already opening significant additional revenue opportunities in 2026 and for 2027. Our leadership team’s steadfast commitment has continually affirmed that our products are timely and essential. Our outreach initiatives have extended across continents, with inroads in Asia, Australia, South Africa, the UK, Germany, Canada, and Latin America, all of which have boosted our sales pipeline.

Relationships are strong with vibrant communications amongst the largest global food manufacturers and include production execution and rollout timetables for the finished FMCG market. 9m) are both reflective of efforts focused on B2B sales. 6m), predominantly due to an increase in finished goods, in preparation for the expected bulk orders anticipated for the Customer 3 product rollout in H2 2026. 9m), predominantly due to higher sales levels achieved in the Period.

2m), predominantly due to increased purchases to build inventory levels needed for the anticipated Customer 3 product rollout in Q4 2026. 9m) due to accrued interest on convertible loan notes. 4m of this liability was resolved upon the conversion of one of the outstanding notes. Operations summary A key focus of the business during H1 2026 was our larger-volume B2B opportunities with several multinational FMCG companies and food manufacturers along with the expansion of our R&D efforts to ensure that we were reactive to market demand.

MicroSalt is now an approved supplier for North and South America for one of the world’s largest food manufacturers as well as US, Canada, and the UK for one of the world’s largest spice and ingredient suppliers. Product innovation remains central to our growth strategy. During the Period, the Company launched MicroSalt Fibre, a low-sodium salt infused with dietary fibre and developed to address the growing nutritional needs of GLP-1 (weight loss and type 2 diabetes management drug) consumers. We have been encouraged by the level of commercial interest generated since launch, demonstrating the potential for further product extensions within the MicroSalt portfolio.

3 billion in annual revenue. The solution is designed to expand MicroSalt's application opportunities across additional food categories and delivery systems. 3m) representing a 60% increase over H1 2025. This includes shipments to existing markets of Canada, Mexico, United States and newly opened markets in the UK and Belgium.

We made significant advancements in strengthening the positioning of our technology platform within the clean-label and health-focused food categories in the Period. In particular, we note that our WISECode range has been positioned as a non-ultra-processed (non-UPF) ingredient solution, aligning with growing industry and consumer demand for minimally processed, recognisable ingredients. This further enhances the attractiveness of the MicroSalt offering to food manufacturers seeking to reduce sodium without compromising product transparency or taste.

MicroSalt also attended several US based and international food shows, which has been the core focus of our sales and outreach efforts. We also invest actively into brand awareness and social media campaigns with a focus on our B2B business. Political & regulatory update The World Health Organisation ("WHO") has set a target of reducing global sodium intake by 30% by 2030, which it estimates will save 7 million lives by 2030. WHO research also found that every US$1 spent on sodium reduction translates to US$12 in healthcare cost savings for treating cardiovascular disease.

Governmental pressure continues to increase with new regulations in Canada for 2026. Additionally, local dieticians and purchasing authorities are taking action, regardless of any legal mandates, to lower sodium. Governmental pressures from the US Food & Drug Administration regarding the use of petroleum-based colours did however postpone a number of low sodium reformulation efforts until Q3/Q4 2026. Governmental pressures on HFSS (high fat salt or sugar) regulation in the UK are also re-igniting sales conversation for both bulk and private label.

Post period end & outlook Looking ahead, our future remains bright, with growing sales volumes, including an expanding range of applications, broader sales channels and an increasing number of countries served. Continued regulatory support for lower-sodium food products provides an important catalyst for growth in both the US and international markets, while supporting the long-term opportunity for MicroSalt to become a key component in the food industry. As announced earlier in September 2026, the Company has also significantly strengthened its balance sheet.

0m before expenses, subject to the necessary share issuance authority being granted at the General Meeting on 2 October 2026. 4m of convertible loan notes into equity in September 2026 has further reduced the Company's debt levels. Together, these developments leave MicroSalt with a significantly strengthened financial position and cash resources to support the business as it continues to scale towards being trading cash flow positive, which is expected when the Customer 3 rollout reaches its forecast volumes.

Since the Period end, this progress has been further recognised through our winning the 2026 Fast Company World Changing Ideas Award, highlighting our contribution to healthier food innovation through our patented sodium-reduction technology. We have also strengthened our network of brand ambassadors through a new partnership with internationally recognised chef and artisan baker Loïc Autret, who brings extensive expertise in artisan breads, viennoiserie and premium bakery products.

Joining existing ambassador Jack Stein, Loïc will support product development and help demonstrate the ability of MicroSalt to reduce sodium in bakery applications without compromising taste or functionality, further strengthening our engagement with customers across the sector. We remain excited by the growing range of possibilities and commercial opportunities for MicroSalt in 2026 and beyond. On behalf of the Board, I would like to thank all our stakeholders for their continued support and contribution to the progress we are making towards our mission and objectives.